Dashboard
Manage Tickers

ANABANAPTYSBIO, INC

Nasdaq anaptysbio.com


$ 25.72 $ 0.04 (0.16 %)    

Wednesday, 08-May-2024 15:59:48 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 439.63 $ 1.40 (0.32 %)
DIA $ 390.50 $ 2.22 (0.57 %)
SPY $ 517.10 $ 1.84 (0.36 %)
TLT $ 90.18 $ -0.54 (-0.6 %)
GLD $ 213.58 $ -0.04 (-0.02 %)
$ 25.68
$ 25.58
$ 25.70 x 100
$ 0.00 x 0
$ 25.51 - $ 26.02
$ 13.36 - $ 27.50
320,769
na
691.41M
$ 0.67
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-11-2024 12-31-2023 10-K
2 11-02-2023 09-30-2023 10-Q
3 08-07-2023 06-30-2023 10-Q
4 05-11-2023 03-31-2023 10-Q
5 03-01-2023 12-31-2022 10-K
6 11-08-2022 09-30-2022 10-Q
7 08-08-2022 06-30-2022 10-Q
8 05-04-2022 03-31-2022 10-Q
9 03-07-2022 12-31-2021 10-K
10 11-04-2021 09-30-2021 10-Q
11 08-09-2021 06-30-2021 10-Q
12 05-04-2021 03-31-2021 10-Q
13 02-25-2021 12-31-2020 10-K
14 11-04-2020 09-30-2020 10-Q
15 08-10-2020 06-30-2020 10-Q
16 05-06-2020 03-31-2020 10-Q
17 03-02-2020 12-31-2019 10-K
18 11-08-2019 09-30-2019 10-Q
19 08-08-2019 06-30-2019 10-Q
20 05-07-2019 03-31-2019 10-Q
21 02-28-2019 12-31-2018 10-K
22 11-08-2018 09-30-2018 10-Q
23 08-07-2018 06-30-2018 10-Q
24 05-08-2018 03-31-2018 10-Q
25 03-05-2018 12-31-2017 10-K
26 11-07-2017 09-30-2017 10-Q
27 08-10-2017 06-30-2017 10-Q
28 05-12-2017 03-31-2017 10-Q
29 03-08-2017 12-31-2016 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

leerink-partners-initiates-coverage-on-anaptysbio-with-outperform-rating-announces-price-target-of-47
Leerink Partners Initiates Coverage On Ana...
04/16/2024 16:10:47

Leerink Partners analyst David Risinger initiates coverage on AnaptysBio (NASDAQ:ANAB) with a Outperform rating and announce...

why-fastenal-shares-are-trading-lower-by-around-7-here-are-other-stocks-moving-in-thursdays-mid-day-session
Why Fastenal Shares Are Trading Lower By A...
04/11/2024 17:33:07

Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter f...

enliven-therapeutics-alpine-immune-sciences-janux-therapeutics-and-other-big-stocks-moving-higher-on-thursday
Enliven Therapeutics, Alpine Immune Scienc...
04/11/2024 14:01:51

U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NA...

wells-fargo-initiates-coverage-on-anaptysbio-with-overweight-rating-announces-price-target-of-56
Wells Fargo Initiates Coverage On AnaptysB...
04/11/2024 13:45:48

Wells Fargo analyst Derek Archila initiates coverage on AnaptysBio (NASDAQ:ANAB) with a Overweight rating and announces Pric...

unveiling-4-analyst-insights-on-anaptysbio
Unveiling 4 Analyst Insights On AnaptysBio
04/01/2024 19:01:13

jp-morgan-maintains-neutral-on-anaptysbio-lowers-price-target-to-28
JP Morgan Maintains Neutral on AnaptysBio,...
04/01/2024 14:06:07

JP Morgan analyst Anupam Rama maintains AnaptysBio (NASDAQ:ANAB) with a Neutral and lowers the price target from $30 to $28.

skin-disease-focused-anaptysbio-earns-analyst-upgrade-on-positive-outlook-for-clinical-triggers
Skin Disease-Focused AnaptysBio Earns Anal...
03/12/2024 18:48:52

AnaptysBio exceeds Q4 2023 earnings expectations, with sales of $9.01 million. Expectations high post-Wedbush upgrade, foreseei...

wedbush-upgrades-anaptysbio-to-outperform
Wedbush Upgrades AnaptysBio to Outperform
03/12/2024 11:11:21

Wedbush analyst David Nierengarten upgrades AnaptysBio (NASDAQ:ANAB) from Neutral to Outperform.

anaptysbio-q4-eps-159-beats-160-estimate-sales-901m-beat-223m-estimate
AnaptysBio Q4 EPS $(1.59) Beats $(1.60) Es...
03/11/2024 20:29:02

AnaptysBio (NASDAQ:ANAB) reported quarterly losses of $(1.59) per share which beat the analyst consensus estimate of $(1.60) by...

btig-initiates-coverage-on-anaptysbio-with-buy-rating-announces-price-target-of-55
BTIG Initiates Coverage On AnaptysBio with...
02/26/2024 12:34:14

BTIG analyst Julian Harrison initiates coverage on AnaptysBio (NASDAQ:ANAB) with a Buy rating and announces Price Target of ...

stifel-initiates-coverage-on-anaptysbio-with-buy-rating-announces-price-target-of-50
Stifel Initiates Coverage On AnaptysBio wi...
02/21/2024 10:43:41

Stifel analyst Alex Schwartz initiates coverage on AnaptysBio (NASDAQ:ANAB) with a Buy rating and announces Price Target of ...

anaptysbio-inc--expects-to-report-that-it-had-cash-and-cash-equivalents-and-investments-of-417m-as-of-december-31-2023
AnaptysBio Inc Expects To Report That It ...
01/05/2024 21:20:26

-SEC Filing

wedbush-reiterates-neutral-on-anaptysbio-maintains-20-price-target
Wedbush Reiterates Neutral on AnaptysBio, ...
11/29/2023 13:21:51

Wedbush analyst David Nierengarten reiterates AnaptysBio (NASDAQ:ANAB) with a Neutral and maintains $20 price target.

Core News & Articles
Anaptys Expands Immune Cell Modulator Pipe...
11/27/2023 21:16:34

Anaptys licenses exclusive global development and commercialization rights to a potential best-in-class BDCA2 modulator portfol...

wedbush-maintains-neutral-on-anaptysbio-raises-price-target-to-20
Wedbush Maintains Neutral on AnaptysBio, R...
11/03/2023 13:56:00

Wedbush analyst David Nierengarten maintains AnaptysBio (NASDAQ:ANAB) with a Neutral and raises the price target from $18 to...

anaptysbio-q3-eps-141-beats-179-estimate-sales-332m-beat-251m-estimate
AnaptysBio Q3 EPS $(1.41) Beats $(1.79) Es...
11/02/2023 21:31:15

AnaptysBio (NASDAQ:ANAB) reported quarterly losses of $(1.41) per share which beat the analyst consensus estimate of $(1.79) by...

ubs-maintains-neutral-on-anaptysbio-lowers-price-target-to-21
UBS Maintains Neutral on AnaptysBio, Lower...
11/01/2023 18:55:18

UBS analyst Eliana Merle maintains AnaptysBio (NASDAQ:ANAB) with a Neutral and lowers the price target from $28 to $21.

anaptysbio-to-present-phase-1-data-on-anb032-its-btla-agonist-antibody-at-the-32nd-eadv-congress
AnaptysBio To Present Phase 1 Data On ANB0...
10/11/2023 13:16:38

why-is-skin-disease-focused-anaptysbio-stock-trading-higher-today
Why Is Skin Disease Focused AnaptysBio Sto...
10/09/2023 13:26:13

AnaptysBio Inc (NASDAQ: ANAB) released topline results from its global Phase 3 GEMINI-1 trial of imsidolimab (IL-36R mAb) in pa...

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
10/09/2023 13:06:06

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION